Global Meningococcal Vaccine Market Size, Share, Trends & Growth Analysis Report 2026-2034

Description

The Meningococcal Vaccine Market size is expected to reach USD 5.16 Billion in 2034 from USD 2.96 Billion (2025) growing at a CAGR of 6.39% during 2026-2034.

The global meningococcal vaccine market has experienced significant growth due to increasing efforts to prevent meningococcal disease, a serious bacterial infection that can cause meningitis and bloodstream infections. Vaccination programs have played a crucial role in reducing the incidence of this disease, particularly among infants, adolescents, and individuals at higher risk.

Key drivers of the meningococcal vaccine market include growing public health initiatives and expanding immunization programs. Governments and healthcare organizations are promoting vaccination campaigns to prevent outbreaks and protect vulnerable populations. Additionally, advancements in vaccine research have led to the development of more effective and broader protection vaccines.

In the future, the meningococcal vaccine market is expected to expand as global healthcare systems strengthen disease prevention strategies. Continued research in vaccine technology and increasing awareness about immunization benefits may support higher vaccination coverage. Furthermore, expanding healthcare infrastructure in developing regions will likely increase access to meningococcal vaccines.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

Bivalent
Quadrivalent
Others

By Brand

Menactra
Menveo
Nimenrix
Trumenba
Bexsero
Others

By Age Group

Infants (0 to 2 years)
Children And Adults (2 years & above)

By Serotype

Serotype A
Serotype B
Serotype C
Serotype W-135
Serotype Y

By Sales Channel

Private
Public

COMPANIES PROFILED

Pfizer Inc, Sanofi, Serum Institute of India Ltd, GSK plc, Merck Co Inc, Walvax Biotechnology Co Ltd, Chongqing Zhifei Biological Products Co Ltd, Baxter International, CSL Limited, Bavarian Nordic Incepta Vaccine Ltd, Sinovac Biotech Ltd, Novartis, Panacea Biotec Ltd
We can customise the report as per your requirements.

Product Code: VMR11212373

Chapter 1. PREFACE

1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

2.1. Market Snapshot
2.2. Segmental Outlook
2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

3.1. Market Lineage Outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Value Chain Analysis
3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
3.6. Porter's Five Forces Analysis
3.7. PESTLE Analysis

Chapter 4. GLOBAL MENINGOCOCCAL VACCINE MARKET: BY TYPE 2022-2034 (USD MN and Million Doses)

4.1. Market Analysis, Insights and Forecast Type
4.2. Bivalent Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
4.3. Quadrivalent Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL MENINGOCOCCAL VACCINE MARKET: BY BRAND 2022-2034 (USD MN and Million Doses)

5.1. Market Analysis, Insights and Forecast Brand
5.2. Menactra Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
5.3. Menveo Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
5.4. Nimenrix Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
5.5. Trumenba Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
5.6. Bexsero Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL MENINGOCOCCAL VACCINE MARKET: BY AGE GROUP 2022-2034 (USD MN and Million Doses)

6.1. Market Analysis, Insights and Forecast Age Group
6.2. Infants (0 to 2 years) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
6.3. Children And Adults (2 years & above) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL MENINGOCOCCAL VACCINE MARKET: BY SEROTYPE 2022-2034 (USD MN and Million Doses)

7.1. Market Analysis, Insights and Forecast Serotype
7.2. Serotype A Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
7.3. Serotype B Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
7.4. Serotype C Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
7.5. Serotype W-135 Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
7.6. Serotype Y Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 8. GLOBAL MENINGOCOCCAL VACCINE MARKET: BY SALES CHANNEL 2022-2034 (USD MN and Million Doses)

8.1. Market Analysis, Insights and Forecast Sales Channel
8.2. Private Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
8.3. Public Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 9. GLOBAL MENINGOCOCCAL VACCINE MARKET: BY REGION 2022-2034(USD MN and Million Doses)

9.1. Regional Outlook
9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
- 9.2.1 By Type
- 9.2.2 By Brand
- 9.2.3 By Age Group
- 9.2.4 By Serotype
- 9.2.5 By Sales Channel
- 9.2.6 United States
- 9.2.7 Canada
- 9.2.8 Mexico
9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
- 9.3.1 By Type
- 9.3.2 By Brand
- 9.3.3 By Age Group
- 9.3.4 By Serotype
- 9.3.5 By Sales Channel
- 9.3.6 United Kingdom
- 9.3.7 France
- 9.3.8 Germany
- 9.3.9 Italy
- 9.3.10 Russia
- 9.3.11 Rest Of Europe
9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
- 9.4.1 By Type
- 9.4.2 By Brand
- 9.4.3 By Age Group
- 9.4.4 By Serotype
- 9.4.5 By Sales Channel
- 9.4.6 India
- 9.4.7 Japan
- 9.4.8 South Korea
- 9.4.9 Australia
- 9.4.10 South East Asia
- 9.4.11 Rest Of Asia Pacific
9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
- 9.5.1 By Type
- 9.5.2 By Brand
- 9.5.3 By Age Group
- 9.5.4 By Serotype
- 9.5.5 By Sales Channel
- 9.5.6 Brazil
- 9.5.7 Argentina
- 9.5.8 Peru
- 9.5.9 Chile
- 9.5.10 South East Asia
- 9.5.11 Rest of Latin America
9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
- 9.6.1 By Type
- 9.6.2 By Brand
- 9.6.3 By Age Group
- 9.6.4 By Serotype
- 9.6.5 By Sales Channel
- 9.6.6 Saudi Arabia
- 9.6.7 UAE
- 9.6.8 Israel
- 9.6.9 South Africa
- 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

10.1. Recent Developments
10.2. Company Categorization
10.3. Supply Chain & Channel Partners (based on availability)
10.4. Market Share & Positioning Analysis (based on availability)
10.5. Vendor Landscape (based on availability)
10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL MENINGOCOCCAL VACCINE INDUSTRY

11.1. Top Companies Market Share Analysis
11.2. Company Profiles
- 11.2.1 Pfizer Inc
- 11.2.2 Sanofi
- 11.2.3 Serum Institute Of India Ltd
- 11.2.4 GSK Plc
- 11.2.5 Merck & Co. Inc
- 11.2.6 Walvax Biotechnology Co. Ltd
- 11.2.7 Chongqing Zhifei Biological Products Co. Ltd
- 11.2.8 Baxter International
- 11.2.9 CSL Limited
- 11.2.10 Bavarian Nordic Incepta Vaccine Ltd
- 11.2.11 Sinovac Biotech Ltd
- 11.2.12 Novartis
- 11.2.13 Panacea Biotec Ltd